Global Tinea Corporis Drugs Market
Global Tinea Corporis Drugs Market

Tinea Corporis Drugs Comprehensive Study by Type (Antifungals, Steroids, Anti-Infective Combinations), Tinea corporis (Tinea corporis (general skin), Tinea cruris (groin), Tinea pedis (feet)), Symptompes (Trichophyton, Microsporum, Epidermophyton), Administration (Lotion, Powder, Cream, Others) Players and Region - Global Market Outlook to 2025

Tinea Corporis Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 250 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Tinea Corporis Drugs Market?

Tinea Corporis is the contagious contamination that creates on the upper layer of the skin. It very well may be happening or produce in any body part however significantly created on the legs and arms especially in the glabrous skin. Fungus corporis normally known as ringworm and seem like ring structure on the skin. Parasitic species that cause fungus corporis are Trichophyton rubrum, Microsporum canis and Epidermophyton floccosum. Tinea Corporis Drugs alludes to fungus anyplace on the body aside from the scalp, whiskers, feet, or hands. This injury presents as an annular plaque with a marginally raised and frequently textured, propelling fringe and is regularly known as ringworm. Every sore may have one or a few concentric rings with red papules or plaques in the middle. As the injury advances, the middle may clear, leaving post-incendiary hypopigmentation or hyperpigmentation.

The market study is being classified by Type (Antifungals, Steroids and Anti-Infective Combinations) and major geographies with country level break-up.

Sun Pharmaceutical (India), Teva (Israel), Glenmark (India), Aurobindo (India), AvKare (United States), Novartis (Switzerland), Sebela Pharmaceuticals Inc. (United States) and Bayer (Germany) are some of the key players profiled in the study.

The global Tinea Corporis Drugs market is fragmented and rely on strategies such as mergers & acquisitions, product development, geographical expansion, and sourcing strategies to enhance their market share. Also, the increase in investments in the music industry is expected to drive the demand for the Tinea Corporis Drugs Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Tinea Corporis Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Tinea Corporis Drugs market by Type, Application and Region.

On the basis of geography, the market of Tinea Corporis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The rise in the prevalence of skin infection such as ringworm
  • The increasing number of cases of dermatological related diseases drives the tinea corporis drugs to demand in the market


Restraints
  • Lack of knowledge for diseases

Opportunities
  • Increased healthcare expenditure. Asia-Pacific

Challenges
  • Use of homemade therapy as a substitute



"FDA regulations number 333.250 Labeling of antifungal drug products. The labeling of the product states, under the heading ‘‘Indications,’’ the phrase listed in paragraph (b)(1)(i) of this section and may contain the additional phrase listed in, paragraph (b)(1)(ii) of this section. Other truthful and non-misleading statements, describing only the indications for use that have been established in paragraph (b) of this section, may also be used, as provided in §330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the Act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce and of unapproved new drugs in violation of section 505(a) of the act. "

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Tinea Corporis Drugs Manufacturer, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Antifungals
  • Steroids
  • Anti-Infective Combinations
By Tinea corporis
  • Tinea corporis (general skin)
  • Tinea cruris (groin)
  • Tinea pedis (feet)

By Symptompes
  • Trichophyton
  • Microsporum
  • Epidermophyton

By Administration
  • Lotion
  • Powder
  • Cream
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise in the prevalence of skin infection such as ringworm
      • 3.2.2. The increasing number of cases of dermatological related diseases drives the tinea corporis drugs to demand in the market
    • 3.3. Market Challenges
      • 3.3.1. Use of homemade therapy as a substitute
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tinea Corporis Drugs, by Type, Tinea corporis, Symptompes, Administration and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Tinea Corporis Drugs (Value)
      • 5.2.1. Global Tinea Corporis Drugs by: Type (Value)
        • 5.2.1.1. Antifungals
        • 5.2.1.2. Steroids
        • 5.2.1.3. Anti-Infective Combinations
      • 5.2.2. Global Tinea Corporis Drugs by: Tinea corporis (Value)
        • 5.2.2.1. Tinea corporis (general skin)
        • 5.2.2.2. Tinea cruris (groin)
        • 5.2.2.3. Tinea pedis (feet)
      • 5.2.3. Global Tinea Corporis Drugs by: Symptompes (Value)
        • 5.2.3.1. Trichophyton
        • 5.2.3.2. Microsporum
        • 5.2.3.3. Epidermophyton
      • 5.2.4. Global Tinea Corporis Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Tinea Corporis Drugs (Volume)
      • 5.3.1. Global Tinea Corporis Drugs by: Type (Volume)
        • 5.3.1.1. Antifungals
        • 5.3.1.2. Steroids
        • 5.3.1.3. Anti-Infective Combinations
      • 5.3.2. Global Tinea Corporis Drugs by: Tinea corporis (Volume)
        • 5.3.2.1. Tinea corporis (general skin)
        • 5.3.2.2. Tinea cruris (groin)
        • 5.3.2.3. Tinea pedis (feet)
      • 5.3.3. Global Tinea Corporis Drugs by: Symptompes (Volume)
        • 5.3.3.1. Trichophyton
        • 5.3.3.2. Microsporum
        • 5.3.3.3. Epidermophyton
      • 5.3.4. Global Tinea Corporis Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Tinea Corporis Drugs (Price)
      • 5.4.1. Global Tinea Corporis Drugs by: Type (Price)
  • 6. Tinea Corporis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sun Pharmaceutical (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Glenmark (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aurobindo (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AvKare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sebela Pharmaceuticals Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Tinea Corporis Drugs Sale, by Type, Tinea corporis, Symptompes, Administration and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Tinea Corporis Drugs (Value)
      • 7.2.1. Global Tinea Corporis Drugs by: Type (Value)
        • 7.2.1.1. Antifungals
        • 7.2.1.2. Steroids
        • 7.2.1.3. Anti-Infective Combinations
      • 7.2.2. Global Tinea Corporis Drugs by: Tinea corporis (Value)
        • 7.2.2.1. Tinea corporis (general skin)
        • 7.2.2.2. Tinea cruris (groin)
        • 7.2.2.3. Tinea pedis (feet)
      • 7.2.3. Global Tinea Corporis Drugs by: Symptompes (Value)
        • 7.2.3.1. Trichophyton
        • 7.2.3.2. Microsporum
        • 7.2.3.3. Epidermophyton
      • 7.2.4. Global Tinea Corporis Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Tinea Corporis Drugs (Volume)
      • 7.3.1. Global Tinea Corporis Drugs by: Type (Volume)
        • 7.3.1.1. Antifungals
        • 7.3.1.2. Steroids
        • 7.3.1.3. Anti-Infective Combinations
      • 7.3.2. Global Tinea Corporis Drugs by: Tinea corporis (Volume)
        • 7.3.2.1. Tinea corporis (general skin)
        • 7.3.2.2. Tinea cruris (groin)
        • 7.3.2.3. Tinea pedis (feet)
      • 7.3.3. Global Tinea Corporis Drugs by: Symptompes (Volume)
        • 7.3.3.1. Trichophyton
        • 7.3.3.2. Microsporum
        • 7.3.3.3. Epidermophyton
      • 7.3.4. Global Tinea Corporis Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Tinea Corporis Drugs (Price)
      • 7.4.1. Global Tinea Corporis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tinea Corporis Drugs: by Type(USD Million)
  • Table 2. Tinea Corporis Drugs Antifungals , by Region USD Million (2014-2019)
  • Table 3. Tinea Corporis Drugs Steroids , by Region USD Million (2014-2019)
  • Table 4. Tinea Corporis Drugs Anti-Infective Combinations , by Region USD Million (2014-2019)
  • Table 5. Tinea Corporis Drugs: by Tinea corporis(USD Million)
  • Table 6. Tinea Corporis Drugs Tinea corporis (general skin) , by Region USD Million (2014-2019)
  • Table 7. Tinea Corporis Drugs Tinea cruris (groin) , by Region USD Million (2014-2019)
  • Table 8. Tinea Corporis Drugs Tinea pedis (feet) , by Region USD Million (2014-2019)
  • Table 9. Tinea Corporis Drugs: by Symptompes(USD Million)
  • Table 10. Tinea Corporis Drugs Trichophyton , by Region USD Million (2014-2019)
  • Table 11. Tinea Corporis Drugs Microsporum , by Region USD Million (2014-2019)
  • Table 12. Tinea Corporis Drugs Epidermophyton , by Region USD Million (2014-2019)
  • Table 13. South America Tinea Corporis Drugs, by Country USD Million (2014-2019)
  • Table 14. South America Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 15. South America Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 16. South America Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 17. South America Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 18. Brazil Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 19. Brazil Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 20. Brazil Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 21. Brazil Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 22. Argentina Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 23. Argentina Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 24. Argentina Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 25. Argentina Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 26. Rest of South America Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 27. Rest of South America Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 28. Rest of South America Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 29. Rest of South America Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 30. Asia Pacific Tinea Corporis Drugs, by Country USD Million (2014-2019)
  • Table 31. Asia Pacific Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 32. Asia Pacific Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 33. Asia Pacific Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 34. Asia Pacific Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 35. China Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 36. China Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 37. China Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 38. China Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 39. Japan Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 40. Japan Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 41. Japan Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 42. Japan Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 43. India Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 44. India Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 45. India Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 46. India Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 47. South Korea Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 48. South Korea Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 49. South Korea Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 50. South Korea Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 51. Taiwan Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 52. Taiwan Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 53. Taiwan Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 54. Taiwan Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 55. Australia Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 56. Australia Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 57. Australia Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 58. Australia Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 59. Rest of Asia-Pacific Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 60. Rest of Asia-Pacific Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 61. Rest of Asia-Pacific Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 62. Rest of Asia-Pacific Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 63. Europe Tinea Corporis Drugs, by Country USD Million (2014-2019)
  • Table 64. Europe Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 65. Europe Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 66. Europe Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 67. Europe Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 68. Germany Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 69. Germany Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 70. Germany Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 71. Germany Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 72. France Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 73. France Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 74. France Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 75. France Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 76. Italy Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 77. Italy Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 78. Italy Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 79. Italy Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 80. United Kingdom Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 81. United Kingdom Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 82. United Kingdom Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 83. United Kingdom Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 84. Netherlands Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 85. Netherlands Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 86. Netherlands Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 87. Netherlands Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 88. Rest of Europe Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 89. Rest of Europe Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 90. Rest of Europe Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 91. Rest of Europe Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 92. MEA Tinea Corporis Drugs, by Country USD Million (2014-2019)
  • Table 93. MEA Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 94. MEA Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 95. MEA Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 96. MEA Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 97. Middle East Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 98. Middle East Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 99. Middle East Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 100. Middle East Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 101. Africa Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 102. Africa Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 103. Africa Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 104. Africa Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 105. North America Tinea Corporis Drugs, by Country USD Million (2014-2019)
  • Table 106. North America Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 107. North America Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 108. North America Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 109. North America Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 110. United States Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 111. United States Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 112. United States Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 113. United States Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 114. Canada Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 115. Canada Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 116. Canada Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 117. Canada Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 118. Mexico Tinea Corporis Drugs, by Type USD Million (2014-2019)
  • Table 119. Mexico Tinea Corporis Drugs, by Tinea corporis USD Million (2014-2019)
  • Table 120. Mexico Tinea Corporis Drugs, by Symptompes USD Million (2014-2019)
  • Table 121. Mexico Tinea Corporis Drugs, by Administration USD Million (2014-2019)
  • Table 122. Tinea Corporis Drugs Sales: by Type(K Tons)
  • Table 123. Tinea Corporis Drugs Sales Antifungals , by Region K Tons (2014-2019)
  • Table 124. Tinea Corporis Drugs Sales Steroids , by Region K Tons (2014-2019)
  • Table 125. Tinea Corporis Drugs Sales Anti-Infective Combinations , by Region K Tons (2014-2019)
  • Table 126. Tinea Corporis Drugs Sales: by Tinea corporis(K Tons)
  • Table 127. Tinea Corporis Drugs Sales Tinea corporis (general skin) , by Region K Tons (2014-2019)
  • Table 128. Tinea Corporis Drugs Sales Tinea cruris (groin) , by Region K Tons (2014-2019)
  • Table 129. Tinea Corporis Drugs Sales Tinea pedis (feet) , by Region K Tons (2014-2019)
  • Table 130. Tinea Corporis Drugs Sales: by Symptompes(K Tons)
  • Table 131. Tinea Corporis Drugs Sales Trichophyton , by Region K Tons (2014-2019)
  • Table 132. Tinea Corporis Drugs Sales Microsporum , by Region K Tons (2014-2019)
  • Table 133. Tinea Corporis Drugs Sales Epidermophyton , by Region K Tons (2014-2019)
  • Table 134. South America Tinea Corporis Drugs Sales, by Country K Tons (2014-2019)
  • Table 135. South America Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 136. South America Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 137. South America Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 138. South America Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 139. Brazil Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 140. Brazil Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 141. Brazil Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 142. Brazil Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 143. Argentina Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 144. Argentina Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 145. Argentina Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 146. Argentina Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 147. Rest of South America Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 148. Rest of South America Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 149. Rest of South America Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 150. Rest of South America Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 151. Asia Pacific Tinea Corporis Drugs Sales, by Country K Tons (2014-2019)
  • Table 152. Asia Pacific Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 153. Asia Pacific Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 154. Asia Pacific Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 155. Asia Pacific Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 156. China Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 157. China Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 158. China Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 159. China Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 160. Japan Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 161. Japan Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 162. Japan Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 163. Japan Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 164. India Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 165. India Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 166. India Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 167. India Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 168. South Korea Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 169. South Korea Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 170. South Korea Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 171. South Korea Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 172. Taiwan Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 173. Taiwan Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 174. Taiwan Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 175. Taiwan Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 176. Australia Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 177. Australia Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 178. Australia Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 179. Australia Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 180. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 181. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 182. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 183. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 184. Europe Tinea Corporis Drugs Sales, by Country K Tons (2014-2019)
  • Table 185. Europe Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 186. Europe Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 187. Europe Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 188. Europe Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 189. Germany Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 190. Germany Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 191. Germany Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 192. Germany Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 193. France Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 194. France Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 195. France Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 196. France Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 197. Italy Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 198. Italy Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 199. Italy Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 200. Italy Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 201. United Kingdom Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 202. United Kingdom Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 203. United Kingdom Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 204. United Kingdom Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 205. Netherlands Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 206. Netherlands Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 207. Netherlands Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 208. Netherlands Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 209. Rest of Europe Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 210. Rest of Europe Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 211. Rest of Europe Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 212. Rest of Europe Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 213. MEA Tinea Corporis Drugs Sales, by Country K Tons (2014-2019)
  • Table 214. MEA Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 215. MEA Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 216. MEA Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 217. MEA Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 218. Middle East Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 219. Middle East Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 220. Middle East Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 221. Middle East Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 222. Africa Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 223. Africa Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 224. Africa Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 225. Africa Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 226. North America Tinea Corporis Drugs Sales, by Country K Tons (2014-2019)
  • Table 227. North America Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 228. North America Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 229. North America Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 230. North America Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 231. United States Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 232. United States Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 233. United States Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 234. United States Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 235. Canada Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 236. Canada Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 237. Canada Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 238. Canada Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 239. Mexico Tinea Corporis Drugs Sales, by Type K Tons (2014-2019)
  • Table 240. Mexico Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2014-2019)
  • Table 241. Mexico Tinea Corporis Drugs Sales, by Symptompes K Tons (2014-2019)
  • Table 242. Mexico Tinea Corporis Drugs Sales, by Administration K Tons (2014-2019)
  • Table 243. Tinea Corporis Drugs: by Type(USD/Units)
  • Table 244. Company Basic Information, Sales Area and Its Competitors
  • Table 245. Company Basic Information, Sales Area and Its Competitors
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Tinea Corporis Drugs: by Type(USD Million)
  • Table 253. Tinea Corporis Drugs Antifungals , by Region USD Million (2020-2025)
  • Table 254. Tinea Corporis Drugs Steroids , by Region USD Million (2020-2025)
  • Table 255. Tinea Corporis Drugs Anti-Infective Combinations , by Region USD Million (2020-2025)
  • Table 256. Tinea Corporis Drugs: by Tinea corporis(USD Million)
  • Table 257. Tinea Corporis Drugs Tinea corporis (general skin) , by Region USD Million (2020-2025)
  • Table 258. Tinea Corporis Drugs Tinea cruris (groin) , by Region USD Million (2020-2025)
  • Table 259. Tinea Corporis Drugs Tinea pedis (feet) , by Region USD Million (2020-2025)
  • Table 260. Tinea Corporis Drugs: by Symptompes(USD Million)
  • Table 261. Tinea Corporis Drugs Trichophyton , by Region USD Million (2020-2025)
  • Table 262. Tinea Corporis Drugs Microsporum , by Region USD Million (2020-2025)
  • Table 263. Tinea Corporis Drugs Epidermophyton , by Region USD Million (2020-2025)
  • Table 264. South America Tinea Corporis Drugs, by Country USD Million (2020-2025)
  • Table 265. South America Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 266. South America Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 267. South America Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 268. South America Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 269. Brazil Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 270. Brazil Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 271. Brazil Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 272. Brazil Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 273. Argentina Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 274. Argentina Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 275. Argentina Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 276. Argentina Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 277. Rest of South America Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 278. Rest of South America Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 279. Rest of South America Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 280. Rest of South America Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 281. Asia Pacific Tinea Corporis Drugs, by Country USD Million (2020-2025)
  • Table 282. Asia Pacific Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 283. Asia Pacific Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 284. Asia Pacific Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 285. Asia Pacific Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 286. China Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 287. China Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 288. China Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 289. China Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 290. Japan Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 291. Japan Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 292. Japan Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 293. Japan Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 294. India Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 295. India Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 296. India Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 297. India Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 298. South Korea Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 299. South Korea Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 300. South Korea Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 301. South Korea Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 302. Taiwan Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 303. Taiwan Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 304. Taiwan Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 305. Taiwan Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 306. Australia Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 307. Australia Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 308. Australia Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 309. Australia Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 310. Rest of Asia-Pacific Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 311. Rest of Asia-Pacific Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 312. Rest of Asia-Pacific Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 313. Rest of Asia-Pacific Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 314. Europe Tinea Corporis Drugs, by Country USD Million (2020-2025)
  • Table 315. Europe Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 316. Europe Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 317. Europe Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 318. Europe Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 319. Germany Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 320. Germany Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 321. Germany Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 322. Germany Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 323. France Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 324. France Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 325. France Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 326. France Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 327. Italy Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 328. Italy Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 329. Italy Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 330. Italy Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 331. United Kingdom Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 332. United Kingdom Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 333. United Kingdom Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 334. United Kingdom Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 335. Netherlands Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 336. Netherlands Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 337. Netherlands Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 338. Netherlands Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 339. Rest of Europe Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 340. Rest of Europe Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 341. Rest of Europe Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 342. Rest of Europe Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 343. MEA Tinea Corporis Drugs, by Country USD Million (2020-2025)
  • Table 344. MEA Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 345. MEA Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 346. MEA Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 347. MEA Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 348. Middle East Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 349. Middle East Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 350. Middle East Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 351. Middle East Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 352. Africa Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 353. Africa Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 354. Africa Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 355. Africa Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 356. North America Tinea Corporis Drugs, by Country USD Million (2020-2025)
  • Table 357. North America Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 358. North America Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 359. North America Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 360. North America Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 361. United States Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 362. United States Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 363. United States Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 364. United States Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 365. Canada Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 366. Canada Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 367. Canada Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 368. Canada Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 369. Mexico Tinea Corporis Drugs, by Type USD Million (2020-2025)
  • Table 370. Mexico Tinea Corporis Drugs, by Tinea corporis USD Million (2020-2025)
  • Table 371. Mexico Tinea Corporis Drugs, by Symptompes USD Million (2020-2025)
  • Table 372. Mexico Tinea Corporis Drugs, by Administration USD Million (2020-2025)
  • Table 373. Tinea Corporis Drugs Sales: by Type(K Tons)
  • Table 374. Tinea Corporis Drugs Sales Antifungals , by Region K Tons (2020-2025)
  • Table 375. Tinea Corporis Drugs Sales Steroids , by Region K Tons (2020-2025)
  • Table 376. Tinea Corporis Drugs Sales Anti-Infective Combinations , by Region K Tons (2020-2025)
  • Table 377. Tinea Corporis Drugs Sales: by Tinea corporis(K Tons)
  • Table 378. Tinea Corporis Drugs Sales Tinea corporis (general skin) , by Region K Tons (2020-2025)
  • Table 379. Tinea Corporis Drugs Sales Tinea cruris (groin) , by Region K Tons (2020-2025)
  • Table 380. Tinea Corporis Drugs Sales Tinea pedis (feet) , by Region K Tons (2020-2025)
  • Table 381. Tinea Corporis Drugs Sales: by Symptompes(K Tons)
  • Table 382. Tinea Corporis Drugs Sales Trichophyton , by Region K Tons (2020-2025)
  • Table 383. Tinea Corporis Drugs Sales Microsporum , by Region K Tons (2020-2025)
  • Table 384. Tinea Corporis Drugs Sales Epidermophyton , by Region K Tons (2020-2025)
  • Table 385. South America Tinea Corporis Drugs Sales, by Country K Tons (2020-2025)
  • Table 386. South America Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 387. South America Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 388. South America Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 389. South America Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 390. Brazil Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 391. Brazil Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 392. Brazil Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 393. Brazil Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 394. Argentina Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 395. Argentina Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 396. Argentina Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 397. Argentina Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 398. Rest of South America Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 399. Rest of South America Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 400. Rest of South America Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 401. Rest of South America Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 402. Asia Pacific Tinea Corporis Drugs Sales, by Country K Tons (2020-2025)
  • Table 403. Asia Pacific Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 404. Asia Pacific Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 405. Asia Pacific Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 406. Asia Pacific Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 407. China Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 408. China Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 409. China Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 410. China Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 411. Japan Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 412. Japan Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 413. Japan Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 414. Japan Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 415. India Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 416. India Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 417. India Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 418. India Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 419. South Korea Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 420. South Korea Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 421. South Korea Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 422. South Korea Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 423. Taiwan Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 424. Taiwan Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 425. Taiwan Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 426. Taiwan Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 427. Australia Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 428. Australia Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 429. Australia Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 430. Australia Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 431. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 432. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 433. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 434. Rest of Asia-Pacific Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 435. Europe Tinea Corporis Drugs Sales, by Country K Tons (2020-2025)
  • Table 436. Europe Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 437. Europe Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 438. Europe Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 439. Europe Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 440. Germany Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 441. Germany Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 442. Germany Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 443. Germany Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 444. France Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 445. France Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 446. France Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 447. France Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 448. Italy Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 449. Italy Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 450. Italy Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 451. Italy Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 452. United Kingdom Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 453. United Kingdom Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 454. United Kingdom Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 455. United Kingdom Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 456. Netherlands Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 457. Netherlands Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 458. Netherlands Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 459. Netherlands Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 460. Rest of Europe Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 461. Rest of Europe Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 462. Rest of Europe Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 463. Rest of Europe Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 464. MEA Tinea Corporis Drugs Sales, by Country K Tons (2020-2025)
  • Table 465. MEA Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 466. MEA Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 467. MEA Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 468. MEA Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 469. Middle East Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 470. Middle East Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 471. Middle East Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 472. Middle East Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 473. Africa Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 474. Africa Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 475. Africa Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 476. Africa Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 477. North America Tinea Corporis Drugs Sales, by Country K Tons (2020-2025)
  • Table 478. North America Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 479. North America Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 480. North America Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 481. North America Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 482. United States Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 483. United States Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 484. United States Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 485. United States Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 486. Canada Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 487. Canada Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 488. Canada Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 489. Canada Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 490. Mexico Tinea Corporis Drugs Sales, by Type K Tons (2020-2025)
  • Table 491. Mexico Tinea Corporis Drugs Sales, by Tinea corporis K Tons (2020-2025)
  • Table 492. Mexico Tinea Corporis Drugs Sales, by Symptompes K Tons (2020-2025)
  • Table 493. Mexico Tinea Corporis Drugs Sales, by Administration K Tons (2020-2025)
  • Table 494. Tinea Corporis Drugs: by Type(USD/Units)
  • Table 495. Research Programs/Design for This Report
  • Table 496. Key Data Information from Secondary Sources
  • Table 497. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tinea Corporis Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Tinea Corporis Drugs: by Tinea corporis USD Million (2014-2019)
  • Figure 6. Global Tinea Corporis Drugs: by Symptompes USD Million (2014-2019)
  • Figure 7. South America Tinea Corporis Drugs Share (%), by Country
  • Figure 8. Asia Pacific Tinea Corporis Drugs Share (%), by Country
  • Figure 9. Europe Tinea Corporis Drugs Share (%), by Country
  • Figure 10. MEA Tinea Corporis Drugs Share (%), by Country
  • Figure 11. North America Tinea Corporis Drugs Share (%), by Country
  • Figure 12. Global Tinea Corporis Drugs: by Type K Tons (2014-2019)
  • Figure 13. Global Tinea Corporis Drugs: by Tinea corporis K Tons (2014-2019)
  • Figure 14. Global Tinea Corporis Drugs: by Symptompes K Tons (2014-2019)
  • Figure 15. South America Tinea Corporis Drugs Share (%), by Country
  • Figure 16. Asia Pacific Tinea Corporis Drugs Share (%), by Country
  • Figure 17. Europe Tinea Corporis Drugs Share (%), by Country
  • Figure 18. MEA Tinea Corporis Drugs Share (%), by Country
  • Figure 19. North America Tinea Corporis Drugs Share (%), by Country
  • Figure 20. Global Tinea Corporis Drugs: by Type USD/Units (2014-2019)
  • Figure 21. Global Tinea Corporis Drugs share by Players 2019 (%)
  • Figure 22. Global Tinea Corporis Drugs share by Players (Top 3) 2019(%)
  • Figure 23. Global Tinea Corporis Drugs share by Players (Top 5) 2019(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 26. Sun Pharmaceutical (India) Revenue: by Geography 2019
  • Figure 27. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva (Israel) Revenue: by Geography 2019
  • Figure 29. Glenmark (India) Revenue, Net Income and Gross profit
  • Figure 30. Glenmark (India) Revenue: by Geography 2019
  • Figure 31. Aurobindo (India) Revenue, Net Income and Gross profit
  • Figure 32. Aurobindo (India) Revenue: by Geography 2019
  • Figure 33. AvKare (United States) Revenue, Net Income and Gross profit
  • Figure 34. AvKare (United States) Revenue: by Geography 2019
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2019
  • Figure 37. Sebela Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Sebela Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 39. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 40. Bayer (Germany) Revenue: by Geography 2019
  • Figure 41. Global Tinea Corporis Drugs: by Type USD Million (2020-2025)
  • Figure 42. Global Tinea Corporis Drugs: by Tinea corporis USD Million (2020-2025)
  • Figure 43. Global Tinea Corporis Drugs: by Symptompes USD Million (2020-2025)
  • Figure 44. South America Tinea Corporis Drugs Share (%), by Country
  • Figure 45. Asia Pacific Tinea Corporis Drugs Share (%), by Country
  • Figure 46. Europe Tinea Corporis Drugs Share (%), by Country
  • Figure 47. MEA Tinea Corporis Drugs Share (%), by Country
  • Figure 48. North America Tinea Corporis Drugs Share (%), by Country
  • Figure 49. Global Tinea Corporis Drugs: by Type K Tons (2020-2025)
  • Figure 50. Global Tinea Corporis Drugs: by Tinea corporis K Tons (2020-2025)
  • Figure 51. Global Tinea Corporis Drugs: by Symptompes K Tons (2020-2025)
  • Figure 52. South America Tinea Corporis Drugs Share (%), by Country
  • Figure 53. Asia Pacific Tinea Corporis Drugs Share (%), by Country
  • Figure 54. Europe Tinea Corporis Drugs Share (%), by Country
  • Figure 55. MEA Tinea Corporis Drugs Share (%), by Country
  • Figure 56. North America Tinea Corporis Drugs Share (%), by Country
  • Figure 57. Global Tinea Corporis Drugs: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Sun Pharmaceutical (India)
  • Teva (Israel)
  • Glenmark (India)
  • Aurobindo (India)
  • AvKare (United States)
  • Novartis (Switzerland)
  • Sebela Pharmaceuticals Inc. (United States)
  • Bayer (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation